These phase II clinical trials investigated a promising novel agent, thought to be a PARP inhibitor with potential synergy with gemcitabine and carboplatin in 2 cohorts of patients with recurrent ovarian cancer. The gene discussed is PARP1; the disease is ovarian carcinoma.